However, it remains to be investigated in further clinical trials whether [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT imaging could outperform immunohistochemistry and ISH analyses as a method to predict treatment outcome in HER2-low breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.